(Total Views: 248)
Posted On: 09/27/2020 11:43:33 AM
Post# of 103413
LXRP Within 2 weeks the coming Altria decision and opportunity, reflecting from the statement posted from the the Altria vision; I include a part from the promotion of the IR firm as well.
"The tranche trigger activation would initiate a staged payment to Lexaria Nicotine LLC. and enable Altria to retain its current exclusivity in the US market for Lexaria's DehydraTECH™ for oral nicotine delivery purposes.
Altria currently holds an existing minority equity stake and board representation in Lexaria Nicotine LLC. and is titled to a non-exclusive license to use DehydraTECH™ worldwide. Lexaria is expected to benefit from an earlier-defined royalty payment schedule if Altria decides to utilize the technology commercially, regardless of additional R&D results"
Altrias own statement; "The tobacco industry is changing – and for the better. The future of our industry is about innovation, harm reduction and informed consumer choice. With FDA regulation of the tobacco industry in place, we're focusing our tremendous resources and talented people on reducing the risk of tobacco products, while expanding choices for adult consumers".
So, we have a down payment of 11 million US dollars, royalty deal set and the change to actual PARTNERSHIP who will increase it`s equity stake big time... AND get 3 directors on the board = big influence on protecting Lexaria, cause they will be a important part of Lexarias future and protecting the investment equals Altrias best interest.
CEO interview on the Altria collaboration, 2 month ago.
https://www.youtube.com/watch?v=t34v4kMKn5w
Read More: https://investorshangout.com/post/view?id=590...z6ZG0PmjW9
"The tranche trigger activation would initiate a staged payment to Lexaria Nicotine LLC. and enable Altria to retain its current exclusivity in the US market for Lexaria's DehydraTECH™ for oral nicotine delivery purposes.
Altria currently holds an existing minority equity stake and board representation in Lexaria Nicotine LLC. and is titled to a non-exclusive license to use DehydraTECH™ worldwide. Lexaria is expected to benefit from an earlier-defined royalty payment schedule if Altria decides to utilize the technology commercially, regardless of additional R&D results"
Altrias own statement; "The tobacco industry is changing – and for the better. The future of our industry is about innovation, harm reduction and informed consumer choice. With FDA regulation of the tobacco industry in place, we're focusing our tremendous resources and talented people on reducing the risk of tobacco products, while expanding choices for adult consumers".
So, we have a down payment of 11 million US dollars, royalty deal set and the change to actual PARTNERSHIP who will increase it`s equity stake big time... AND get 3 directors on the board = big influence on protecting Lexaria, cause they will be a important part of Lexarias future and protecting the investment equals Altrias best interest.
CEO interview on the Altria collaboration, 2 month ago.
https://www.youtube.com/watch?v=t34v4kMKn5w
Read More: https://investorshangout.com/post/view?id=590...z6ZG0PmjW9
(0)
(0)
Robert
Scroll down for more posts ▼
